Aprea Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Aprea Therapeutics, Inc. - overview
Established
2003
Location
Doylestown, PA, US
Primary Industry
Biotechnology
About
Aprea Therapeutics, Inc. , based in the US, focuses on the development of innovative therapeutics targeting DNA Damage Response (DDR) mechanisms to treat various cancer types, improving treatment efficacy with minimized side effects. Founded in 2003 and headquartered in Boston, US, Aprea Therapeutics specializes in cancer therapeutics. The company has raised a total of USD 5.
51 mn through multiple funding rounds, with the most recent being a Private Placement/Follow on in February 2023. The company’s CEO is Oren Gilad, and it was founded by Vladimir Bykov. Aprea has engaged in 9 deals, with its last deal occurring on October 2, 2019. Aprea Therapeutics specializes in developing innovative DNA Damage Response (DDR) targeted cancer therapeutics aimed at addressing specific genetic mutations associated with various cancer types.
The company's core product offerings include small molecule inhibitors designed to enhance the efficacy of cancer treatments while minimizing toxicity to healthy tissues. These therapeutics are crafted to widen the therapeutic window, focusing on the precise matching of treatments to patients based on their unique cancer profiles. Aprea’s product pipeline targets multiple genetic mutations to improve treatment outcomes, thereby catering to a diverse client base that includes healthcare providers and oncology specialists in regions such as North America and Europe. The end users of Aprea’s therapies are primarily oncology patients seeking effective treatments for their specific cancer conditions, with the aim of significantly altering their treatment journey.
In 2023, Aprea Therapeutics reported revenue of USD 583,231. The company also faced an EBITDA loss of USD 15,464,911 for the same year. Aprea generates revenue through collaborations and partnerships with healthcare institutions and pharmaceutical companies, focusing on B2B transactions. The structure of these partnerships may involve licensing agreements and joint ventures, enabling the company to leverage external expertise while advancing its therapeutic pipeline.
Revenue may also be generated through clinical trial collaborations and research funding, allowing Aprea to bring its products to market effectively. The company’s flagship product offerings are positioned to attract significant interest from healthcare providers, given their targeted approach to treatment. Aprea Therapeutics aims to leverage its recent funding from the Private Placement in February 2023 to further develop its clinical drug ATRN-119, pre-clinical drug ATRN-W1051, and support general corporate purposes. The company is also looking to expand its market reach, particularly in North America and Europe, by launching new products tailored to specific genetic mutations in cancer.
The funding will facilitate ongoing clinical trials and enhance research capabilities, thereby bolstering Aprea's position in the oncology market.
Current Investors
Versant Ventures, 5AM Ventures, Sectoral Asset Management
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.aprea.com
Company Stage
Mature
Total Amount Raised
Subscriber access only
Aprea Therapeutics, Inc. - timeline of key events
Aprea Therapeutics, Inc. - financials
| Fiscal Year Ended | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | - | - | - | - | - | - | - | - | - |
| % Revenue Growth (YoY) | - | - | - | - | - | - | - | - | - |
| EBITDA (USD) | (15,200,000) | (15,500,000) | (28,045,904) | (53,471,854) | (36,857,274) | (112,924,249) | - | - | - |
| Operating Income (USD) | (15,200,000) | (15,500,000) | (28,216,158) | (53,701,464) | (37,128,951) | (113,110,694) | - | - | - |
| Operating Margin | - | - | - | - | - | - | - | - | - |
| % EBITDA Margin | - | - | - | - | - | - | - | - | - |
| NET Income (USD) | (15,200,000) | (15,500,000) | (28,059,807) | (53,478,812) | (37,127,303) | (112,662,027) | - | - | - |
| % Net Margin | - | - | - | - | - | - | - | - | - |
Aprea Therapeutics, Inc. - employee data
Aprea Therapeutics, Inc. - key contacts
| Name | Position | Start Date | End Date | Vcard | Bio | ||
|---|---|---|---|---|---|---|---|
| Board member | BM | ||||||
| Board member | BM | ||||||
| Member of the Board of Directors | BM |
BM Board Member
Want to see more?
Request a demo for full access to this profile
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.